Anti-mutant-CALR Antibody Combination Therapy for MPN
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Philadelphia-negative myeloproliferative neoplasms (MPNs) associated with mutant CALR proteins are inadequate in terms of safety and effectiveness.
Innovation Solution
A pharmaceutical combination of an antibody specifically binding to a mutant CALR protein and a selected anticancer drug, such as a JAK inhibitor or interferon, to enhance antitumor effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If low-molecular weight anticancer drugs (alkylating agents, platinum preparations, antimetabolites, etc.) are used for treating Philadelphia-negative MPNs, then some therapeutic effect is achieved, but safety issues such as myelosuppression and hematotoxicity occur and effectiveness is insufficient
Solution Approach 1:
The patent changes the therapeutic parameter from conventional low-molecular weight anticancer drugs to a combination of anti-mutant-CALR antibody and another drug. This parameter change resolves the contradiction by providing a new mechanism of action that specifically targets mutant-CALR expressing cells while sparing normal hematopoietic cells, thereby improving effectiveness without causing severe myelosuppression and hematotoxicity
Solution Approach 2:
The patent employs a composite therapeutic approach by combining an anti-mutant-CALR antibody with another drug (such as JAK inhibitors, interferons, or other anticancer agents). This composite therapy achieves synergistic effects, improving overall therapeutic effectiveness while the antibody component provides tumor-specific targeting to reduce harmful side effects on normal cells
2Reliability
If conventional anticancer drugs are used alone, then treatment is simple, but antitumor effect is insufficient
Solution Approach 1:
The patent merges two therapeutic agents into a single treatment regimen: an anti-mutant-CALR antibody and another drug. The antibody provides specific targeting to mutant-CALR expressing tumor cells, while the companion drug provides additional antitumor activity through different mechanisms. This combination achieves synergistic antitumor effects that are superior to monotherapy, resolving the contradiction between treatment simplicity and effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly improves antitumor efficacy compared to monotherapy, providing a more effective therapeutic option for treating cancers with mutant CALR expression.
Implementation Method 1
an antibody which specifically binds to a mutant calreticulin protein or a functional fragment
Data Source
AI summary
A pharmaceutical which exhibits sufficient anticancer effects by using an antibody which binds to a mutant CALR protein and another anticancer agent in combination. A pharmaceutical for preventing and/or treating a cancer, including an antibody which specifically binds to a mutant calreticulin protein or a functional fragment thereof and a drug selected from the group consisting of an alkylating agent, a platinum preparation, an antimetabolite, a ribonucleotide reductase inhibitor, a nucleotide analog, a topoisomerase inhibitor, a microtubule polymerization inhibitor, an antitumor antibiotic, an interferon, a cytokine preparation, a molecular targeting drug, a nucleic acid synthesis inhibitor, a jak inhibitor, and a cancer immunotherapeutic agent in combination.